why choose us

First received: May 25, 2023

Clinical Trial: A Study of HS-20094 in T2DM Participants

Study Status: Completed

Recruit Status: RECRUITING

Condition: Type 2 Diabetes

Study Type: INTERVENTIONAL


Official Title: A Multiple-dose, Randomized, Double-blind, Placebo and Positive Controlled Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-20094 in Subjects With Typ

Brief Summary: This is a randomized, placebo and active-control, multiple-dose, phase IIa trial.Patients were randomly assigned to receive HS-20094 (12 patients), placebo (3 patients), or active control drug Semaglutide injection (3 patients) in a 4:1:1 ratio to each of four dose cohorts of 5 mg, 10 mg, 15 mg, and 20 mg.HS-20094 and placebo were administered in a double-blind design by subcutaneous injection once a week for a total of four times, and the dose was gradually increased weekly (2.5-2.5-5-5mg, 5-510-10 mg, 5-10-15-15…

Read more